![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
News|Videos|December 9, 2016
Using FDG-PET to Guide Hodgkin Lymphoma Treatment
Author(s)Peter Johnson, MD
This interview examines the role of functional imaging to direct therapy (escalation or de-escalation) for early and advanced Hodgkin lymphoma.
Advertisement
In this interview, Peter Johnson, MD, of the University of Southampton in the United Kingdom, discusses the results of trials testing the role of FDG–positron emission tomography (PET) to direct therapy (escalation or de-escalation) for patients with both early and advanced Hodgkin lymphoma.
Dr. Johnson spoke at an education session on how Hodgkin lymphoma is treated today and the challenges ahead at the 58th Annual Meeting of the American Society of Hematology, held December 3–6 in San Diego, California.
Advertisement
Related to this article
Health Canada approved epcoritamab plus lenalidomide and rituximab for relapsed/refractory grade 1 to 3a follicular lymphoma, backed by the EPCORE FL-1 trial.
Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.
Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.
An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.
The updated NCCN guidelines for myeloproliferative neoplasms recommend rusfertide as a Category 1 option across both low- and high-risk polycythemia vera.
![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
Jasmine Zain, MD, described how preexisting CHIP mutations should inform preinfusion risk counseling and treatment selection.
Advertisement
Advertisement
Trending on CancerNetwork
1
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
2
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
3
Acting on a HER2 Result and Navigating Access to Therapy
4
FDA Clears TriNav Advance for Expanded Liver Embolization Access
5